Version 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-
|
|
- Hilda Sharp
- 5 years ago
- Views:
Transcription
1 Introduction: These guidelines represent systematically developed statements to assist in the provision of quality assured HER2 testing in breast and gastric/ gastro-oesophageal carcinoma. They are based on current published international guidelines. They were presented to the Faculty of Pathology Quality Assurance Working Group and to the Academy of Medical Laboratory Scientists for comment by their membership before adoption and recommendation for implementation. Each year the authors will consider, in conjunction with current literature update, whether the guidelines need to be revised Version 1 of these Guidelines were ratified by the Professional bodies and adopted in Version 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations- Wolff AC et al. Recommendations for Human Epidermal Growth Factor Receptor Testing in Breast Cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology: 2013; 31 (31): Guideline Update history: American Society of Clinical Oncology (ASCO) Practice Guideline Committee approval: April 26, 2013 College of American Pathologists (CAP) approval: June 2013.
2 Proposal for HER2 National Testing Criteriarecommendations by the HER2 sub-group This group was initially convened in May 2010 from a larger group of pathologists and medical scientists involved in laboratory testing for HER2 across Irish pathology departments. All pathologists known to be involved in HER2 testing across Irish laboratories were invited to initial meetings to discuss the wider issues relating to HER2 testing and the need to refine testing recommendations and guidelines for the Irish laboratories. From this group, a sub-group was appointed. The aim was to have representation on the subgroup from pathologists and senior/chief medical scientists from the centres who were represented in the main group. The remit of the sub-group was to review current international recommendations for HER2 testing in the literature (1-10) and, from this, to make recommendations for Irish laboratories involved in IHC and ISH (FISH and CISH) HER2 testing for breast and gastric cancer. HER2 testing sub- group membership: Dr Mairead Griffin, St James s Hospital Mr John Harford, St Vincents University Hospital Dr Susan Kennedy, St Vincents University Hospital Ms Deirdre Mc Mahon, St Vincents University Hospital Mr Kieran Mc Allister, Mater Hospital Dr Fionnuala O Connell, Cork University Hospital Dr Tony O Grady, Royal College of Surgeons Ireland & Beaumont Hospital Dr Cecily Quinn, St Vincents University Hospital Dr Margaret Sheehan, Galway University Hospital (Chairperson) Ms Jan Walker, St James s Hospital Dr Michael Jeffers, AMNCH- Chairperson of the Advisory Board, in attendance at sub-group meetings and correspondence. Subsequent to publication of the revised guidelines by ASCO/ CAP in 2013 (11), the group re-convened to review the updated Guidelines and presented here as Version 2. Review Authors for Version 2, HER2 National Testing Criteria Dr Margaret Sheehan, BreastCheck/ Galway University Hospital Dr Cecily Quinn, BreastCheck/ St Vincent s University Hospital Dr Tara- Jane Browne, Cork University Hospital Dr Mairead Griffin, St James s Hospital, Dublin Version 2 circulated to wider group March Discussed at open forum 25/3/14. Feedback/ comments incorporated in the final document Version 2 finalised 31st March 2014 **indicates changes to guidelines in Version 2 update The HER2 subgroup meetings have been facilitated by Roche.
3 HER2 Testing Criteria- consensus from sub-group Specimen for testing: Core biopsy or excision specimen as per local practise No evidence in literature that either specimen is preferable Mandatory Criteria GENERAL CRITERIA IHC and ISH Formalin fixation (10% neutral buffered Formalin) Immediate fixation of core Slicing of excision specimens with fixation same day/next day Duration fixation 6-72 hours ** Sections for IHC <6 weeks old Positive and negative controls with each IHC run Participation in technical IHC NEQAS (or other recognised EQA scheme) Laboratory accredited/in process of accreditation Comment: Slicing of excision and fixation same day/next day may present a problem for specimens received late on a Friday- local steps should be taken to avoid this where possible INTERPRETATION CRITERIA Reporting categories IHC (0, 1+, 2+, 3+) Changes in categorisation criteria for IHC scores 0,1+,2+,3+ see Fig 1 ** **Key changes in IHC scoring: Critical threshold of cell membrane staining reduced from 30% tumour cells to 10% tumour cells for all reporting categories IHC score 0 now includes some weak/barely perceptible staining in 10% or less of tumour cells (previously scored 1+) IHC incomplete weak/ moderate membrane staining in >10% tumour cells now categorised as IHC score 2+ (previously scored 1+) ISH testing of all IHC 2+ cases IHC score only invasive tumour (not DCIS) EXCLUSION CRITERIA Core biopsies fixed <1 hour
4 Strong IHC membrane staining in internal normal ducts/lobules Controls not stained as expected Excessive crush/edge artefact in core Excess cytoplasmic staining obscuring membrane staining Very little tumour in core repeat on excision specimen Comment: individual cases need to be evaluated on criteria above on a case by case basis VALIDATION OF TEST CRITERIA Number of cases >50 >95% concordance for completion validation process Validation of IHC against ISH Any alteration to the technique requires revalidation of the technique ISH TESTING CRITERIA ISH testing all IHC 2+ cases Chromosome 17 probe included in ISH test Minimum 20 cells counted for a homogenous case (amplified or non amplified) Score only invasive carcinoma (not DCIS) IHC 2+ area used to guide ISH assessment Borderline category ratio ** this category now eliminated **Categories of ISH reporting See Fig 2, 3. Heterogeneity CISH testing validated against FISH ISH negative- Average HER2 copy number <4.0 signals/cell and HER2:CEP17 ration<2.0 ISH equivocal- average HER2 copy number >=4.0 and <6.0 signals/cell ISH positive- Average HER2 copy number >=6.0 signals /cell and/or HER2:CEP 17 ratio >=2.0 Use of HER2 copy numbers and/or HER2:CEP 17 ratio to categorise using dualsignal (HER2 gene) assay (dual-probe ISH) Additional fields counted **heterogenous tumours- second contiguous population of cells with increased HER2 signals (>10% of tumour cells on slide), separate counting of at least 20 nonoverlapping cells in this area to be included in report REPORTING CRITERIA IHC reporting- clone used to be stated in report
5 ISH- probes used to be stated in report WORKLOAD CRITERIA HER2 testing (IHC and ISH) for both medical scientists and pathologists should be restricted to small numbers of individuals in accordance with the workload of the laboratory to ensure the individual has the optimum experience in this area.(*) (See comment) An individual pathologist must be reporting a reasonable number of cases (*) A laboratory performing a small number of cases has responsibility to reconsider it appropriate to meet with the testing guidelines and should consider referral to a larger laboratory for testing QUALITY ASSURANCE CRITERIA Regular internal audits of results (every 6-12 months depending on volume of workload being tested). Comparison of results with international anticipated overall rates for each category of IHC reporting and ISH amplification rates NEQAS (or other recognised EQA scheme) results to be reviewed by the pathologists and scientists REPEAT TESTING ** Repeat testing of recurrent / metastatic disease should be carried out where material is available Optional Criteria: GENERAL CRITERIA Positive control on each test case slide Use of TMAs for controls INTERPRETATION CRITERIA ISH testing of % of 0, 1+ and 3+ cases VALIDATION OF TEST CRITERIA Number of cases >100 REPORTING CRITERIA IHC double reporting of all cases ISH- number of cells counted stated in the report
6 QUALITY ASSURANCE CRITERIA Test reporting medical scientist and pathologist participation in scoring workshops as available REPEAT TESTING ** Repeat testing of HER2 suggested where certain morphological features of the tumour are regarded as challenging the molecular test result, or other equivocal test outcomes These include: initial HER2 negative result in Grade 3 carcinoma carcinoma on excision which is morphologically distinct from that seen on NCB biopsy initial IHC score 2+ and reflex ISH test equivocal (see above for definition)- consider an alternative ISH assay or repeat testing on new tissue Indeterminate for HER2 (see below for definition) Comment: Repeat testing is recommended in the ASCO/CAP 2013 updated guidelines in the above circumstances. Critical review of these updated guidelines by the Nottingham group (12) points out that supportive evidence for these Repeat Testing guidelines is not provided. For this reason we have included these, for now, under Optional Criteria in this guideline update, subject to revision pending further published data. INDETERMINATE FOR HER2 ** Category defined more specifically in the updated ASCO/CAP guidelines 2013 by the presence of technical issues interfering with test performance or assay. These include: inadequate specimen handling artefacts which limit interpretation test failure due to any other cause Repeat testing is recommended using another specimen. * Comment: Workload volumes for a testing laboratory The UK Group have made recommendations that a laboratory should carry out a minimum of 250 IHC tests per year and 100 FISH tests a year 5,9. The CAP guidelines do not specify a workload minimum 6.
7 This subgroup discussed this in relation to Irish laboratories where 8 centres of cancer care have been designated, each of which performs breast work. An occasional additional laboratory will also do such work affiliated with one of the 8 cancer centres. It was felt that the workload per laboratory guidelines did not address number of tests carried out per individual medical scientist or pathologist, which is felt to be as critical as overall workload volume per laboratory. With specialised breast reporting, individual pathologists in laboratories with differing HER2 testing workload may report a similar and adequate number of cases.
8 Gastric HER2 testing: There was agreement that this area of HER2 testing is still evolving with similarities and certain differences (interpretation/ scoring of IHC) from breast HER2 testing. The following overall guidelines were agreed at this stage, with anticipation that this area will be updated as literature and experience in this area expands. The following guidelines were agreed based on current literature: Criteria for specimen fixation, processing, test validation are as per breast HER2 testing Definition of negative, borderline, positive for gastric HER2 IHC is not the same as for breast and also differs for biopsy material and excision material. The interpretation and scoring criteria for IHC of Hofmann et al should be currently applied (8) QA for gastric HER2 testing should be as for breast and it is recommended that a laboratory involved in gastric HER2 testing should have QA HER2 expertise with breast (to include NEQAS or equivalent participation) HER2 is currently recognised in the treatment of metastatic or locally advanced gastric cancer. The sub-group would recommend testing all such patients, as identified by the MDM group locally. Testing of all gastric cancers (ie not just metastatic/locally advanced) would need to be decided locally as directed by local policy and laboratory facility to carry out same. **The current Updates ASCO/ CAP guidelines refer to HER2 testing in breast only and do not address gastric/ oesophago-gastric adenocarcinoma. Abbreviations: IHC- Immunohistochemical staining FISH- Fluorescent in situ hybridisation CISH- Chromogenic in situ hybridisation QA Quality assurance NEQAS- National external quality assessment scheme NCB- Needle core biopsy TMA- Tissue microarray
9 References: 1. Ellis IO et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53: Bilous M et al. Current Perspectives on HER2 testing: A Review of National Testing Guidelines. Mod Pathol 2003; 16(2): Ellis IO, Bartlett J, Dowsett M et al Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57; P Fitzgibbon et al. Interlaboratory comparison of immunohistochemical testing for HER2.Results of CAP 2004 and 2005 tissue microaray study. Arch Pathol Lab Med. 130: M Dowsett et al. HER2 testing in the UK: Consensus from a national consultation. J Clin Pathol 2007; 60: Wolff A et al. American Society of Clinical Oncology/ College of American Pathologists Guideline Recommendations for Human Epidermal Growth factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007; 131: Dowsett M et al. Standardisation of HER2 testing: results of an international proficiency- testing ring study. Mod Pathol 2007; 20: Hofmann M, Stoss O, Buttner R, van de Vijver M et al. Assessment of a HER2 scoring system for gastric cancer: results from a valiation Study. Histopathology 2008; 52; Walker R, Bartlett J, Dowsett M et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008; 61; T Garcia-Caballero et al. Determination of HER2 amplification in primary breast cancer using dual in situ hybridisation is comparable to fluorescence in situ hybridisation. Histopathology 2010, 56: Wolff AC et al. Recommendations for Human Epidermal Growth Factor Receptor Testing in Breast Cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology: 2013; 31 (31): E-pub Rakha EA, Lee AHS, Ellis IO. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: critical review of their implications for routine practise. Histopathology 2013 (acepted Dec 25th) Accepted Article, doi: 10/1111/his
10 Appendix HER2 Testing Algorithinms Fig 1. Algorithm for evaluation of human epidermal growth factor receptor 2 (HER2) protein expression by immunohistochemistry (IHC) assay of the invasive component of a breast cancer specimen. Although categories of HER2 status by IHC can be created that are not covered by these definitions, in practice they are rare and if encountered should be considered IHC 2_ equivocal. ISH in situ hybridization. NOTE: the final reported results assume that there is no apparent histopathologic discordance observed by the pathologist. (*) Readily appreciated using a low-power objective and observed within a homogeneous and contiguous invasive cell population.
11 Fig 2. Algorithm for evaluation of human epidermal growth factor receptor 2 (HER2) gene amplification by in situ hybridization (ISH) assay of the invasive component of a breast cancer specimen using a single-signal (HER2 gene) assay (single-probe ISH). Amplification in a single-probe ISH assay is defined by examining the average HER2 copy number. If there is a second contiguous population of cells with increased HER2 signals per cell, and this cell population consists of more than 10%of tumor cells on the slide (defined by image analysis or visual estimation of the ISH or immunohistochemistry [IHC] slide), a separate counting of at least 20 nonoverlapping cells must also be performed within this cell population and also reported. Although categories of HER2 status by ISH can be created that are not covered by these definitions, in practice they are rare and if encountered should be considered ISH equivocal (see Data Supplement 2E). NOTE: the final reported results assume that there is no apparent histopathologic discordance observed by the pathologist. (*) Observed in a homogeneous and contiguous population.
12 Fig 3. Algorithm for evaluation of human epidermal growth factor receptor 2 (HER2) gene amplification by in situ hybridization (ISH) assay of the invasive component of a breast cancer specimen using a dual-signal (HER2 gene) assay (dual-probe ISH). Amplification in a dual-probe ISH assay is defined by examining first the HER2/CEP17 ratio followed by the average HER2 copy number (see Data Supplement 2E for more details). If there is a second contiguous population of cells with increased HER2 signals per cell, and this cell population consists of more than 10% of tumor cells on the slide (defined by image analysis or visual estimation of the ISH or immunohistochemistry [IHC] slide), a separate counting of at least 20 nonoverlapping cells must also be performed within this cell population and also reported. Although categories of HER2 status by ISH can be created that are not covered by these definitions, in practice they are rare and if encountered should be considered ISH equivocal (see Data Supplement 2E). NOTE. The final reported results assume that there is no apparent histopathologic discordance observed by the pathologist. (*) Observed in a homogeneous and contiguous population. ( ) See Data Supplement 2E for more information on these rare scenarios.
Optimal algorithm for HER2 testing
Optimal algorithm for HER2 testing The revised definition of IHC 2+ (equivocal) is invasive breast cancer with Weak to moderate complete membrane staining observed in >10% of tumor cells. (see Figure 1
More informationGuideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -
Guideline Subject: ASCO CAP 2018 HER2 Testing for Breast Cancer Guidelines - Recommendations for Practice in Australasia Approval Date: December 2018 Review Date: December 2022 Review By: HER2 testing
More informationFirst released in 2007 and updated in 2013, the recommendations
Special Article Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Antonio
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationEARLY ONLINE RELEASE
EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #449 (NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies National Quality Strategy Domain: Efficiency and Cost Reduction 2017 OPTIONS
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationIntroduction. The HER2 Testing Expert Panel has identified five Clinical Questions that form the core of this Focused Update.
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Focused Update Wolff, et al. Introduction
More informationQuantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer
Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine
More informationData Supplement 1: 2013 Update Rationale and Background Information
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology /College of American Pathologists Clinical Practice Guideline Update (edited
More informationReviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:
Reviewer's report Title: Validation of HER2 testing with core needle biopsy specimens from primary breast cancers in terms of interobserver reproducibility and concordance with surgically resected specimens
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #449 (NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful
More informationKristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD
AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
More informationAspects of quality in breast pathology. Andrew Lee Nottingham University Hospitals
Aspects of quality in breast pathology Andrew Lee Nottingham University Hospitals British breast pathology EQA: performance issues Ian Ellis Friday 8.30 am National breast screening pathology audit 2015
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationDetermination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?
Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #450 (NQF 1858): Trastuzumab Received By Patients With AJCC Stage I (T1c) III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy National Quality Strategy Domain: Effective Clinical
More informationHER2 ISH (BRISH or FISH)
Assessment Run H14 2018 HER2 ISH (BRISH or FISH) Material Table 1. Content of the multi-block used for the NordiQC HER2 ISH assessment, run H14 HER2 IHC* IHC score Dual - SISH** FISH*** FISH*** HER2/chr17
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationWhat is HER2 positive breast cancer in 2018? Updated ASCO-CAP guidelines. Giuseppe Viale University of Milan European Institute of Oncology
What is HER2 positive breast cancer in 2018? Updated ASCO-CAP guidelines Giuseppe Viale University of Milan European Institute of Oncology Mission accomplished! First alarming results Breast Intergroup
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast Version: Template Posting Date: January 2018 Includes requirements from the 2017 CAP Accreditation
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationCollege of American Pathologists. Pathology Performance Measures included in CMS 2012 PQRS
College of American Pathologists Pathology Performance Measures included in CMS 2012 PQRS Breast Cancer Resection Pathology Reporting Measure #99 pt category (primary tumor) and pn category (regional lymph
More informationAssessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray
Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray Hui Chen, Aysegul A Sahin, Xinyan Lu, Lei Huo, Rajesh R Singh, Ronald Abraham, Shumaila Virani, Bal Mukund Mishra, Russell Broaddus,
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationReporting of Breast Cancer Do s and Don ts
Reporting of Breast Cancer Do s and Don ts 7 th SGH Annual Breast Pathology Course Professor Michael Bilous Conjoint Professor Western Sydney University Consultant Pathologist, Australian Clinical Labs,
More informationComparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 44 49 Available online at www.sciencedirect.com jo u r n al hom epage: http://www.elsevier.com/locate/rpor Original article Comparison of
More informationQuality Indicators - Anatomic Pathology- HSC/STC Jul-Sep 2 nd Qtr. Apr-Jun 1 st Qtr
Eastern Health Volume 86 Page 001 CIHRT Exhibit P-3595 Page 1 INDICATOR Financial Overtime Hours / FTE Workload Increase - FTE equivalent Workload Quality Indicators - Anatomic Pathology- HSC/STC TOTAL
More informationCME/SAM. Abstract. Anatomic Pathology / HER2/neu Results in Breast Cancer
Anatomic Pathology / HER2/neu Results in Breast Cancer Effect of Ischemic Time, Fixation Time, and Fixative Type on HER2/neu Immunohistochemical and Fluorescence In Situ Hybridization Results in Breast
More informationOn May 4 and 5, 2002, the College of American Pathologists
College of American Pathologists Conference Conference Summary, Strategic Science Symposium Her-2/neu Testing of Breast Cancer Patients in Clinical Practice Richard J. Zarbo, MD, DMD; M. Elizabeth H. Hammond,
More informationHER2/neu Evaluation of Breast Cancer in 2019
HER2/neu Evaluation of Breast Cancer in 2019 A.A. Sahin, M.D. Professor of Pathology and Translation Molecular Pathology Section Chief of Breast Pathology ERBB2 (HER2) Background 185-kDa membrane protein
More informationAddendum report coding for the National Quality Improvement Programme in Histopathology: a multi-institutional audit
Addendum report coding for the National Quality Improvement Programme in Histopathology: a multi-institutional audit S. Mahon 1,3, D. Catargiu 2, S. Phelan 2, S. Crowther 3, N. Swan 1. St. Vincent s University
More informationSystem-wide Ownership Group: Allina Health Breast Program Committee. Hospital Division Quality Council: August 2018
Oncology Clinical Service Line System-wide Consensus Guidelines: Evaluation and Management of Breast Lumpectomy and Mastectomy Specimens by Surgeons and Pathologists These guidelines apply to clinical
More informationBreast Cancer Interpretation Guide
Breast Cancer Interpretation Guide UCT D O R P NEW ERBB2/ C E P S ht e ZytoLig lor Prob o C l a u 2D D17S12 ng to the i d r o c c a ting for re-tes idelines 2013 ASCO Gu Breast Cancer Interpretation Guide
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More information# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
#1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationAbstract. Anatomic Pathology / HER2 Gene Amplification in Breast Cancer
Anatomic Pathology / HER2 Gene Amplification in Breast Cancer HER2 Gene Amplification in Breast Cancer A Rogues Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations
More informationCOMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME
COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME Maria Lunardi MD Anatomic Pathology Fracastoro Hospital San Bonifacio, Verona -Italy HER2-neu
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationAssessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver
Assessors report for ciqc Run 37: BRAF V600E (April 2014) Assessors: B Gilks, R Wolber, K Ung, P Tavassoli, J Garratt and J Won (recorder) Assessment performed on Tuesday, July 29, 2014, at Lions Gate
More informationMBP AP 3 Core Curriculum
MBP AP 3 Core Curriculum The MBP AP3 core curriculum focuses on providing pathologists with the knowledge and skills needed to be a vital member of the patient care team. Further, the curriculum fulfills
More informationDiagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Pathology Pathology Versions 2004 2017: Blohmer / Costa / Fehm / Friedrichs / Huober / Kreipe / Lück / Schneeweis / Sinn /
More informationBreast Cancer Services in Ireland
Breast Cancer Services in Ireland European Commission Joint Research Centre, Ispra March 14 th 2013 Dr Jerome Coffey MD, FRCPI, FRCR, FFR RCSI Radiation Oncology Advisor on behalf of Dr Susan O Reilly
More informationQuality Assurance and Quality Control in the Pathology Dept.
Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012 Pathology as
More informationJournal of Breast Cancer
ORIGINAL ARTICLE Journal of Breast Cancer J Breast Cancer 2009 December; 12(4): 235-40 DOI: 10.4048/jbc.2009.12.4.235 Comparison of Silver-Enhanced in situ Hybridization and Fluorescence in situ Hybridization
More informationIntroduction 1. Executive Summary 5
Roman_pages 20-09-2005 21:01 Pagina IX Table of contents Introduction 1 Executive Summary 5 1. Epidemiological guidelines for quality assurance in breast cancer screening 15 1.10 Introduction 17 1.20 Local
More informationPROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT
PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT Author: Dr Sally Ann Hales On behalf of the Breast and pathology CNGs Written: March 2005 Reviewed by CNG: June 2009 &
More informationAssessment performed on Friday, September 18, 2015, at Vancouver General Hospital
Assessors report for ciqc Run 49: ATRX (June 2015) Assessors: S Yip and J Won (recorder) Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital Background The combined application
More informationAssessment Run B HER-2 IHC. HER-2/chr17 ratio**
Assessment Run B2 20 HER-2 IHC Material The slide to be stained for HER-2 comprised the following 5 tissues: IHC HER-2 Score* (0, +, 2+,3+) FISH HER-2/chr7 ratio**. Breast ductal carcinoma 0..3 2. Breast
More informationAssessment Run B HER2 IHC
Assessment Run B26 208 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, +, 2+, 3+) FISH: HER2 gene/chr 7 ratio**. Breast carcinoma, no. 2+..3
More informationAssessment Run B HER2 IHC
Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationGenetics Quality and Accreditation workshop Manchester 17 th May 2017
Genetics Quality and Accreditation workshop Manchester 17 th May 2017 Katrina Rack Oxford CEQAS What is CEQAS Types of schemes Scheme update Highlights 2016 Key recommendations CEQAS Background External
More informationHER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer Yanjun Hou, MD, PhD, 1 Hiroaki Nitta, PhD, 2 and Zaibo Li, MD, PhD 1 From the
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationQuality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024
Quality in Control ROS1 Analyte Control Product Codes: HCL022, HCL023 and HCL024 Contents What is ROS1? 2 The Role of ROS1 in Cancer 3 ROS1 Assessment 3 ROS1 Analyte Control Product Details 4 ROS1 Analyte
More informationHER2 status in breast cancer: experience of a Spanish National Reference Centre
Clin Transl Oncol (2011) 13:000-000 DOI RESEARCH ARTICLES HER2 status in breast cancer: experience of a Spanish National Reference Centre Marta Cuadros Carlos Cano Francisco Javier López Paloma Talavera
More informationT he HER2/neu type 1 tyrosine kinase growth factor
710 ORIGINAL ARTICLE HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis
More informationIntratumoral Heterogeneity in Breast Cancer: A Case Report and Molecular Discussion
Original Case Report Article Middle East Journal of Cancer; July October 20152018; 6(3): 9(4): 339-343 Intratumoral Heterogeneity in Breast Cancer: A Case Report and Molecular Discussion Akbar Safaei,
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationReview of cellular pathology governance, breast reporting and immunohistochemistry at. Sherwood Forest Hospitals NHS Foundation Trust
Review of cellular pathology governance, breast reporting and immunohistochemistry at Sherwood Forest Hospitals NHS Foundation Trust A report prepared for the Care Quality Commission in respect of diagnostic
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationSurgical Pathology Lab of the Future. Thomas M. Grogan, M.D. Professor of Pathology, University of Arizona Founder, Ventana Medical Systems, Inc.
Surgical Pathology Lab of the Future Thomas M. Grogan, M.D. Professor of Pathology, University of Arizona Founder, Ventana Medical Systems, Inc. 28 April 2010 Objective Demonstrate how the next generation
More informationNordiQC External Quality Assurance in Immunohistochemistry
NordiQC External Quality Assurance in Immunohistochemistry Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark AALBORG (~ 200.000 inhabitants)
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More informationExpression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer
MOLECULAR AND CLINICAL ONCOLOGY 2: 751-755 Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer RYOSUKE SHIBATA 1,
More informationUpdate on the Practical Management of HER2-Positive Breast Cancer
Update on the Practical Management of HER2-Positive Breast Cancer Antonio C. Wolff, MD, FACP Breast Cancer Program Easy Questions from Joyce HER2 testing and equivocal results TCH vs ACTH options Subcentimeter
More informationUpdate on the Practical Management of HER2-Positive Breast Cancer
Update on the Practical Management of HER2-Positive Breast Cancer Antonio C. Wolff, MD, FACP Breast Cancer Program San Diego, Aug 5 2011 Easy Questions from Joyce HER2 testing and equivocal results TCH
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationBrief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies
Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Victoria Sujoy, MD, Mehrdad Nadji, MD, and Azorides R. Morales, MD From
More informationMultidisciplinary Breast Pathology
Multidisciplinary Breast Pathology Advanced Learning Series MANUAL This Multidisciplinary Breast Pathology manual is current as of October, 2018. Information is subject to change. CURRICULUM The MBP Advanced
More informationGuideline for the Diagnosis of Breast Cancer
Guideline for the Diagnosis of Breast Cancer Version History Version Date Brief Summary of Change Issued 2.0 May 2007 Approved by the Governance Committee 2.0 25.11.08 Discussed at the NSSG 2.1 5.12.08
More informationCC01 - Colon Cancer Tissue Microarray
Reveal Biosciences offers Histochemical Staining, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Whole Slide Imaging, and Quantitative Image Analysis on any TMA CC01 - Colon Cancer Tissue Microarray
More informationInterpretive Diagnostic Error Reduction in Surgical Pathology and Cytology
Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology Guideline from the College of American Pathologists (CAP) Pathology and Laboratory Quality Center and the Association of Directors
More informationGenetic heterogeneity in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases
Modern Pathology () 5, 683 688 & USCAP, Inc. All rights reserved 893-395/ $3. 683 Genetic heterogeneity in HER/neu testing by fluorescence in situ hybridization: a study of 5 cases Martin C Chang,,3, Janet
More informationHuman Papillomavirus Testing in Head and Neck Carcinomas
Human Papillomavirus Testing in Head and Neck Carcinomas Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine 12/18/2017 Overview
More informationThree Hours Thirty Minutes
INTERPRETATION HER2 IQFISH pharmdx TM Interpretation Guide Three Hours Thirty Minutes it s about time Breast carcinoma (FFPE) stained with HER2 IQFISH pharmdx Gastric cancer (FFPE) stained with HER2 IQFISH
More informationIT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm
I N T E R P R E TAT I O N IQFISH pharmdx Interpretation Guide TM HER2 IQFISH pharmdxtm TOP2A IQFISH pharmdxtm Breast carcinoma (FFPE) stained with HER2 IQFISH pharmdx Breast carcinoma (FFPE) stained with
More information05/07/2018. Organisation. The English screening programme what is happening? Organisation. Bowel cancer screening in the UK is:
Organisation The English screening programme what is happening? Phil Quirke Lead Pathologist Bowel Cancer Screening PHE England Bowel Cancer Screening Pathology Committee Started 2006 with roll out 4 devolved
More informationGOALS AND OBJECTIVES BREAST PATHOLOGY
GOALS AND OBJECTIVES BREAST PATHOLOGY LEVEL: PGY2, PGY3, PGY5 A number of these rotations are introductory in nature, as they are major subspecialties, and are followed by two more blocks in PGY-3, during
More informationUniversity of Groningen
University of Groningen Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer van der Vegt, Bert; de Bock, Gertruida H; Bart, Jos; Zwartjes, N.G.; Wesseling,
More informationInterpretation of Breast Pathology in the Era of Minimally Invasive Procedures
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine Jacksonville Medical Director, UF Health Breast Center Chief of Pathology
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationDepartment of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA 2
Hindawi Publishing Corporation Pathology Research International Volume 2012, Article ID 947041, 7 pages doi:10.1155/2012/947041 Clinical Study The Effect of Cold Ischemia Time and/or Formalin Fixation
More informationNIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 January ; 19(1): 144 147. doi:10.1158/1055-9965.epi-09-0807. Feasibility Study for Collection
More informationHER2 FISH pharmdx TM Interpretation Guide - Breast Cancer
P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment
More informationVernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we
9e avondsymposium: "Nieuwe ontwikkelingen in de behandeling van NSCLC" 9 november 2016, UMCG Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we Wim Timens Professor and Chair
More informationSTANDARDS FOR UPPER GI CANCERS 2004
STANDARDS FOR UPPER GI CANCERS 2004 Source: CSCG Title: UPPER GI CANCERS STANDARDS Version: 10/CONSULTATION Page 1 of 33 1. INTRODUCTION TO THE CANCER STANDARDS 1.1 These Cancer Standards replace the previous
More informationDiagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018
Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018 Dr. Tzahi Neuman Dep.Of Pathology Hadassah Medical Center Jerusalem, Israel, (tneuman@hadassah.org.il) Disclosure: 1 no conflicts of
More informationUtility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology
Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology Ugur Ozerdem, M.D. 1 Abstract Background: There is a paradigm shift in breast biopsy philosophy. In
More informationBreast Cancer Diversity Various Disease Subtypes Clinical Diversity
Breast Cancer Predictive Factor Testing: The Challenge and Importance of Standardizing Pre- Analytic Variables David G. Hicks MD Professor of Pathology & Laboratory Medicine Director of Surgical Pathology
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Measure #99 (NQF 0391): Breast Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationDr. Shari Srinivasan, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland
Draft Laboratory Testing for Tumour Markers V1.0 Authors Dr. Shari Srinivasan, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland Dr. Gerard Boran, Consultant Chemical Pathologist,
More information